Paclitaxel liposome combined therapy with cisplatin aged middle-late lung squamous cell carcinomas of the efficacy and side effects

Abstract

Objective To explore the clinical efficacy and toxicity of paclitaxel liposome combined with cisplatin in the treatment of elderly patients with advanced lung squamous cell carcinoma. Methods 66 elderly patients with advanced lung squamous cell carcinoma who were admitted to Shanxi Dayi Hospital and were selected as the study criteria from January 2013 to January 2015(all patients with stageⅢ/Ⅳlung cancer). They were randomly assigned to group (LP group, GP group, each of 33 cases), and group LP was treated with paclitaxel liposome plus cisplatin, the GP group was treated with gemcitabine plus cisplatin. Compare the efficacy, long-term survival rate and toxicity of the two groups of primary lung lesions and metastatic lymph nodes. Results There was no significant difference in objective remission rate and control rate between LP group and GP group after chemotherapy(P>0.05); in group LP, the objective remission rate and control rate of metastatic lymph nodes in group were significantly higher than that of GP group, and the difference was statistically significant(P 0.05), while the two group PFS compared, LP group was significantly higher than the GP group, the difference was statistically significant (P 0.05). Conclusions The curative effect of paclitaxel liposome combined with cisplatin in the treatment of elderly patients with advanced lung squamous cell carcinoma is accurate, not only to the original lesion regions has good treatment effect, but also can reduce the toxic and side reaction of gastrointestinal tract, blood and other, the patient can tolerate. For lymph node metastasis can be obtained more high disease-free survival, it is worth promoting. Key words: Elderly patients with advanced lung squamous cell carcinoma; Paclitaxel liposome; Ⅲ/Ⅳ stage lung cancer; Toxic and side effects